Roche perspectives on Tamiflu

Clinical Microbiology and Infection

Volumn 21, Issue 3, 2015, Pages 226-229

  Clinch, B ^a   Smith, J ^b  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Data sharing; Independent analysis; Influenza; Oseltamivir; Roche perspective

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; OSELTAMIVIR; ENZYME INHIBITOR; SIALIDASE;

ANTIVIRAL THERAPY; ASTHMA; ATTITUDE; AUTHORITY; BACTERIAL INFECTION; CHRONIC DISEASE; CLINICAL STUDY; COCHRANE LIBRARY; CONFUSION; DRUG DESIGN; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE QUALITY; HUMAN; IMMUNOCOMPROMISED PATIENT; INFLUENZA; LICENCE; LOWER RESPIRATORY TRACT INFECTION; OBSERVATIONAL STUDY; PANDEMIC; PATIENT CODING; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTRATION; RESPIRATORY TRACT INFECTION; REVIEW; SWITZERLAND; SYMPTOM; TREATMENT INDICATION; WORLD HEALTH ORGANIZATION; ANTAGONISTS AND INHIBITORS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; INFORMATION DISSEMINATION; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; INFORMATION DISSEMINATION; NEURAMINIDASE; OSELTAMIVIR; TREATMENT OUTCOME;

EID: 84933533896     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.01.014     Document Type: Review

References (40)

1. Lew W., Chen X., Kim C.U. Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Curr Med Chem 2000, 7:663-672.
2. Tamiflu. EPAR-product Information. Annex I-European summary of product characteristics. Available at: [accessed 10.12.14]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000402/WC500033106.pdf.
3. Tamiflu. Highlights of prescribing information. Available at: [accessed 10.12.14]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021087s060,021246s043lbl.pdf.
4. Treanor J.J., Hayden F.G., Vrooman P.S., Barbarash R., Bettis R., Riff D., et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000, 283:1016-1024.
5. Nicholson K.G., Aoki F.Y., Osterhaus A.D., Trottier S., Carewicz O., Mercier C.H., et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000, 355:1845-1850. [Erratum: Lancet 2000; 356: 1856].
6. Whitley R.J., Hayden F.G., Reisinger K.S., Young N., Dutkowski R., Ipe D., et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001, 20:127-133. [Erratum: Pediatr Infect Dis J 2001; 20: 421].
7. Welliver R., Monto A.S., Carewicz O., Schatteman E., Hassman M., Hedrick J., et al. Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001, 285:748-754.
8. Hayden F.G., Belshe R., Villanueva C., Lanno R., Hughes C., Small I., et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. JInfect Dis 2004, 189:440-449.
9. Johnston S.L., Ferrero F., Garcia M.L., Dutkowski R. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J 2005, 24:225-232.
10. Ison M.G., Szakaly P., Shapira M.Y., Kriván G., Nist A., Dutkowski R. Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients. Antivir Ther 2012, 17:955-964.
11. Whitley R.J., Boucher C.A., Lina B., Nguyen-Van-Tam J.S., Osterhaus A., Schutten M., et al. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). Clin Infect Dis 2013, 56:1197-1205. [Erratum: Clin Infect Dis 2014; 58: 1203].
12. Kamal M.A., Acosta E.P., Kimberlin D.W., Gibiansky L., Jester P., Niranjan V., et al. The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach. Clin Pharmacol Ther 2014, 96:380-389.
13. Fiore A.E., Fry A., Shay D., Gubareva L., Bresee J.S., Uyeki T.M. US Centers for Disease Control and Prevention. Antiviral agents for the treatment and chemoprophylaxis of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011, 60:1-28.
14. US Centers for Disease Control and Prevention CDC recommendations for influenza antiviral medications remain unchanged 10 April 2014, Available at:, [accessed 10.12.14]. http://www.cdc.gov/media/haveyouheard/stories/Influenza_antiviral2.html.
15. World Health Organization. WHO guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses. Revised February 2010. Available at: [accessed 30.11.14]. http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf.
16. European Centre for Disease Prevention and Control ECDC Interim guidance: public health use of influenza antivirals during influenza pandemics 18 August 2009, Available at:, [accessed 10.12.14]. http://www.ecdc.europa.eu/en/publications/Publications/0907_GUI_Public_Health_use_of_Influenza_Antivirals_during_Influenza_Pandemic.pdf.
17. World Health Organization. Essential medicines selection: oseltamivir (inclusion). Available at: [accessed 30.11.14]. http://www.who.int/selection_medicines/committees/expert/17/application/oseltamivir/en/.
18. Treanor J. Reduction in the symptoms and complications of influenza A and B in patients treated with oseltamivir (the Time-to-Treatment Study Group). The 38th Annual Meeting of the Infectious Diseases Society of America, September 7-10 2000, New Orleans. Abstract 611.
19. Martin C., Mahoney P., Ward P. Oral oseltamivir reduces febrile illness in patients considered at high risk of influenza complications [abstract W22-7]. Options for the control of influenza IV 2001, 807-811. Excerpta Medica.
20. UK National Health Service. The care.data programme-collecting information for the health of the nation. Available at: [accessed 22.12.14]. http://www.england.nhs.uk/ourwork/tsd/care-data/.
21. Roche Trials Database. Roche global policy on sharing of clinical trials data. Available at: [accessed 12.12.14]. http://roche-trials.com/dataSharingPolicy.action.
22. Jefferson T., Jones M.A., Doshi P., Del Mar C.B., Hama R., Thompson M.J., et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014, 4:CD008965.
23. Clinch B., Smith J., Kenwright A. Response to: Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014, 348:g2545.
24. Clinch B., Smith J., Kenwright A., Surujbally B., Harding J. Roche feedback on "Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children." 26 October 2014, Available at:, [accessed 22.12.14]. https://editorial-unit.cochrane.org/cochrane-review-neuraminidase-inhibitors-influenza.
25. Kaiser L., Wat C., Mills T., Mahoney P., Ward P., Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003, 163:1667-1672.
26. Hernán M.A., Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011, 53:277-279.
27. Ebell M.H., Call M., Shinholser J. Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials. Fam Pract 2012, 30:125-133.
28. Wingfield W.L., Pollack D., Grunert R. Therapeutic efficacy of amantadine HC1 and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. NEngl J Med 1969, 281:579.
29. Almond M.H., McAuley D.F., Wise M.P., Griffiths M.J. Influenza-related pneumonia. Clin Med 2012, 12:67-70.
30. Chertow D.S., Memoli M.J. Bacterial coinfection in influenza: a grand rounds review. JAMA 2013, 309:275-282.
31. Howard W.A., Peiris M., Hayden F.G. Report of the 'Mechanisms of Lung Injury and Immunomodulator Interventions in Influenza' workshop 21 March 2010, 453-454. Ventura, California, USA, Influenza Other Respir Viruses 2011; 5.
32. Muthuri S.G., Venkatesan S., Myles P.R., Leonardi-Bee J., Al Khuwaitir T.S., Al Mamun A., et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014, 2:395-404. PRIDE Consortium Investigators, Nguyen-Van-Tam JS.
33. Peters P.H., Moscona A., Schulman K.L., Barr C.E. Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005. Medscape J Med 2008, 10:131.
34. Piedra P.A., Schulman K.L., Blumentals W.A. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics 2009, 124:170-178.
35. US Centers for Disease Control and Prevention Influenza antiviral medications: summary for clinicians 3 December 2014, Available at:, [accessed 10.12.14]. http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm.
36. European Centre for Disease Prevention and Contol New and updated evaluations of neuraminidase inhibitors for preventing and treating influenza published 2 June 2014, Available at:, [accessed 10.12.14]. http://ecdc.europa.eu/en/activities/sciadvice/_layouts/forms/Review_DispForm.aspx?List=a3216f4c-f040-4f51-9f77-a96046dbfd72%26ID=764.
37. Public Health England. The use of antivirals for the treatment and prophylaxis of influenza PHE summary of current guidance for healthcare professionals. Available at: [accessed 10.12.14]. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/370673/AV_full_guidance.pdf.
38. Infectious Disease Society of America Statement by the Infectious Disease Society of America (IDSA) on the recent publication on "Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children." April 2014, Available at:, [accessed 10.12.14]. http://www.idsociety.org/Influenza_Statement.aspx.
39. Gøtzsche P.C. European governments should sue Roche and prescribers should boycott its drugs [electronic response to Godlee F. Open letter to Roche about oseltamivir trial data]. BMJ 2012, 345:e7689.
40. Dobson J., Whitley R.J., Pocock S., Monto A.S. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015, 10.1016/S0140-6736(14)62449-1.